SIMULATION MODEL OF IBRUTINIB IN TREATMENT OF RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL)

被引：3
|
作者：
Peng, S. [1 ]
Sorensen, S. [1 ]
Pan, F. [1 ]
Dorman, E. [1 ]
Sun, S. [2 ]
Van Sanden, S. [3 ]
Sengupta, N. [4 ]
Gaudig, M. [5 ]
机构：
[1] Evidera, Bethesda, MD USA
[2] Janssen, Raritan, NJ USA
[3] Univ Hosp Leuven, Leuven, Belgium
[4] Janssen Pharmaceut Inc, Raritan, NJ USA
[5] Janssen Pharmaceut Inc, Neuss, Germany
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2196
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN38
引用
收藏
页码：A620 / A620
页数：1
相关论文
共 50 条
  • [1] Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL).
    Epperla, Narendranath
    Hamadani, Mehdi
    Ahn, Kwang Woo
    Oak, Eunhye
    Cashen, Amanda F.
    Kanate, Abraham Sebastian
    Calzada, Oscar
    Farmer, Zachary Luke
    Tallarico, Michael
    Nabhan, Chadi
    Costa, Luciano J.
    Kenkre, Vaishalee Padgaonkar
    Ghosh, Nilanjan
    Cohen, Jonathon Brett
    Hari, Parameswaran
    Fenske, Timothy S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Ibrutinib in refractory mantle cell lymphoma or relapsed data update
    Paillassa, Jerome
    HEMATOLOGIE, 2015, 21 (05): : 257 - 259
  • [3] Radioimmunotherapy (RIT) of relapsed or refractory mantle cell lymphoma (MCL)
    Elstrom, R
    Chong, E
    Andreadis, C
    Shrikanthan, S
    Downs, L
    Fellin, E
    Tsai, D
    Nasta, S
    Svoboda, J
    Maffi, J
    Alavi, A
    Schuster, S
    ANNALS OF ONCOLOGY, 2005, 16 : 170 - 170
  • [4] A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma
    Lee, Yong-Pyo
    Jung, Ye Ji
    Cho, Junhun
    Ko, Young Hyeh
    Kim, Won Seog
    Kim, Seok Jin
    Yoon, Sang Eun
    BLOOD RESEARCH, 2023, 58 (04) : 208 - 220
  • [5] Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
    Wang, Michael L.
    Rule, Simon
    Martin, Peter
    Goy, Andre
    Auer, Rebecca
    Kahl, Brad S.
    Jurczak, Wojciech
    Advani, Ranjana H.
    Romaguera, Jorge E.
    Williams, Michael E.
    Barrientos, Jacqueline C.
    Chmielowska, Ewa
    Radford, John
    Stilgenbauer, Stephan
    Dreyling, Martin
    Jedrzejczak, Wieslaw Wiktor
    Johnson, Peter
    Spurgeon, Stephen E.
    Li, Lei
    Zhang, Liang
    Newberry, Kate
    Ou, Zhishuo
    Cheng, Nancy
    Fang, Bingliang
    McGreivy, Jesse
    Clow, Fong
    Buggy, Joseph J.
    Chang, Betty Y.
    Beaupre, Darrin M.
    Kunkel, Lori A.
    Blum, Kristie A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (06): : 507 - 516
  • [6] Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: Precog 0404
    Cohen, Jonathon B.
    Jegede, Opeyemi
    Portell, Craig A.
    Hamadani, Mehdi
    Diefenbach, Catherine S.
    David, Kevin A.
    Fletcher, Christopher D.
    Landsburg, Daniel J.
    Mantha, Suparna
    Kahl, Brad S.
    BLOOD, 2022, 140 : 6487 - 6488
  • [7] Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
    Balasubramanian, Sriram
    Schaffer, Michael
    Deraedt, William
    Davis, Cuc
    Stepanchick, Emily
    Aquino, Regina
    Yuan, Zhilong
    Kranenburg, Britte
    Avivi, Irit
    Dreyling, Martin
    Rule, Simon
    Wang, Michael
    Zhuang, Sen Hong
    Rizo, Aleksandra
    Lenz, Georg
    BLOOD, 2014, 124 (21)
  • [8] ECONOMIC EVALUATION OF IBRUTINIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA IN MEXICO
    Carlos, F.
    Herrera, M.
    Salazar, A.
    Aguirre, A.
    Gonzalez-Michaca, L.
    VALUE IN HEALTH, 2016, 19 (03) : A249 - A249
  • [9] Ibrutinib and rituximab association: interest of a chemotherapy free treatment in relapsed or refractory mantle cell lymphoma
    Philippe, Laure
    HEMATOLOGIE, 2016, 22 (01): : 12 - 13
  • [10] Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) and Treatment-Naive (TN) Mantle Cell Lymphoma (MCL)
    Lakhotia, Rahul
    Pittaluga, Stefania
    Phelan, James
    Yang, Yandan
    Davies-Hill, Theresa
    Simard, Jillian
    Muppidi, Jagan
    Huang, Da Wei
    Thomas, Craig
    Ceribelli, Michele
    Tosto, Frances
    Pradhan, Amynah
    Juanitez, Anna
    Rimsza, Lisa
    Jacob, Allison
    Simmons, Heidi
    Steinberg, Seth
    Jaffe, Elaine
    Staudt, Louis
    Roschewski, Mark
    Wilson, Wyndham
    Melani, Christopher
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S461 - S461
12345